Results 41 to 50 of about 167,999 (361)

Influence of Crohn’s disease related polymorphisms in innate immune function on ileal microbiome [PDF]

open access: yes, 2019
We have previously identified NOD2 genotype and inflammatory bowel diseases (IBD) phenotype, as associated with shifts in the ileal microbiome (“dysbiosis”) in a patient cohort.
Ciorba, Matthew A   +13 more
core   +3 more sources

Cutaneous Crohn’s disease of the vulva after a total colectomy and without gastrointestinal manifestations: A case report

open access: yesSAGE Open Medical Case Reports, 2019
Crohn’s disease has many cutaneous manifestations. We report a case of a 54-year-old woman, who had non-contiguous vulvar Crohn’s disease despite a total colectomy and the absence of gastrointestinal Crohn’s disease on ileoscopy.
Michal Bohdanowicz   +2 more
doaj   +1 more source

Crohn's disease activity index and Vienna classification - Is it worthwhile to calculate before surgery? [PDF]

open access: yes, 2006
Background: Crohn's disease (CD) patients with increased disease activity may reveal an increased risk for perioperative complications. The `Crohn's disease activity index' (CDAI) and the `Vienna classification' (VC) were developed for standardized ...
A. Beham   +29 more
core   +1 more source

Crohn’s Disease: a Role of Gut Microbiota and Nod2 Gene Polymorphisms in Disease Pathogenesis

open access: yesActa Medica, 2014
Crohn’s disease is a chronic immune-mediated intestinal inflammation targeted against a yet incompletely defined subset of commensal gut microbiota and occurs on the background of a genetic predisposition under the influence of environmental factors ...
Lucia Hrnčířová   +3 more
doaj   +1 more source

Additional file 5: of Genome analysis of E. coli isolated from Crohnâ s disease patients

open access: yes, 2017
Phage sensitivity test of E. coli CD-isolates (see Methods). (DOC 45Â kb)
Rakitina, Daria   +24 more
openaire   +1 more source

Phenotyping Healthcare Use 2–3 Decades Before the First Multiple Sclerosis Demyelinating Event

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Phenotype hospital, physician, and emergency department (ED) visits by diagnoses and specialty up to 29 years pre‐multiple sclerosis (MS) onset versus a matched population without MS. Methods We identified people with MS (PwMS) using population‐based administrative data from Ontario, Canada (1991–2020).
Helen Tremlett   +8 more
wiley   +1 more source

Mechanisms of Intestinal Epithelial Barrier Dysfunction by Adherent-Invasive Escherichia coli. [PDF]

open access: yes, 2016
Pathobiont expansion, such as that of adherent-invasive Escherichia coli (AIEC), is an emerging factor associated with inflammatory bowel disease. The intestinal epithelial barrier is the first line of defense against these pathogens.
McCole, Declan F, Shawki, Ali
core   +1 more source

Prediction of Perianal Fistula in Crohn’s Disease by Computed Tomography Enterography

open access: yesThe Turkish Journal of Gastroenterology
Background/Aims: The purpose of this study was to investigate whether computed tomography enterography can be used to predict the presence of perianal fistula in Crohn’s disease patients.
Genghuan Ni   +4 more
doaj   +1 more source

Sweet Syndrome and Pulmonary Tuberculosis in a CrohnÂ’s Disease Patient Treated with Anti-TNFα

open access: yesJournal of Gastrointestinal & Digestive System, 2015
A 36-year-old man with Crohn’s Disease (CD), under infliximab therapy, was admitted with fever and skin lesions on the face, trunk and upper limbs. Skin biopsy was consistent with Sweet Syndrome (SS). He was treated with corticosteroids, with transient clinical improvement, but without healing of skin lesions.
Ana Paula Oliveira   +7 more
openaire   +2 more sources

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy